Quince Therapeutics (QNCX) Other financing activities (2019 - 2025)

Quince Therapeutics has reported Other financing activities for 7 years, with the latest figure at $37000.0 in Q4 2025.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $37000.0 in Q4 2025; TTM through Jun 2026 was $37000.0, a 79.78% decrease from a year earlier, with the FY2025 full-year figure at $220000.0, down 2.22% from the prior year.
• Other financing activities was $37000.0 for Q4 2025 at Quince Therapeutics, down from $96000.0 in the prior quarter.
• The five-year high for Other financing activities was $4.7 million in Q3 2021, with the low at $10000.0 in Q3 2023.
• Average Other financing activities over 5 years is $471875.0, with a median of $72000.0 recorded in 2023.
• The sharpest annual moves came in 2021 and 2022: Other financing activities jumped 1183.87% in 2021, then sank 99.7% in 2022.
• Over 5 years, Other financing activities stood at $990000.0 in 2021, then sank by 98.59% to $14000.0 in 2022, then soared by 307.14% to $57000.0 in 2023, then slumped by 38.6% to $35000.0 in 2024, then gained by 5.71% to $37000.0 in 2025.
• The last three Other financing activities figures came in at $37000.0 (Q4 2025), $96000.0 (Q2 2025), and $87000.0 (Q1 2025), per Business Quant data.